Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

First Axl inhibitor enters clinical trials

Nature Biotechnology volume 31, pages 775–776 (2013)Cite this article

Subjects

Axl and Mer are both members of the TAM receptor family, which also includes Tyro3, a kinase that is particularly abundant in the brain. All three are activated by a common ligand, Growth Arrest–specific protein 6 (Gas6), and they ordinarily play an embryonic developmental role in cell survival, migration and differentiation. High levels of Axl expression have been correlated with poor survival in many types of cancer, including breast cancer (Proc. Natl. Acad. Sci. USA 107, 1124–1129, 2010), acute myeloid leukemia (Amer. Soc. Hematol. Annual Meeting, San Diego 2011), glioblastoma multiforme (Clin. Cancer Res. 14, 130–138, 2008) and osteosarcoma (Biochem. Biophys. Res. Commun. 435, 493–500, 2013). In addition, activation of Axl kinase has been identified as one mechanism by which lung cancers can develop resistance to therapies targeting EGFR, such as Tarceva (erlotinib) (Nat. Genet. 44, 852–60, 2012).

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Author information

Authors and Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sheridan, C. First Axl inhibitor enters clinical trials. Nat Biotechnol 31, 775–776 (2013). https://doi.org/10.1038/nbt0913-775a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0913-775a

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing